Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
Emory University
Vanderbilt-Ingram Cancer Center
Jonsson Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
The Christie NHS Foundation Trust
British Columbia Cancer Agency
Centre Henri Becquerel
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
AHS Cancer Control Alberta
AHS Cancer Control Alberta
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Radiation Therapy Oncology Group
Memorial Sloan Kettering Cancer Center
Ontario Clinical Oncology Group (OCOG)